In this issue:
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
2-cm vs 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm
Outcomes of brain metastases during treatment with anti–PD-1 in patients with metastatic melanoma
Adjuvant ipilimumab vs placebo after complete resection of stage III melanoma
Age favoured OS in metastatic melanoma patients treated with anti-PD1 inhibitor
Nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment
Patients’ views about skin selfexamination after treatment for localised melanoma
Reproductive factors and risk of melanoma
INN in SLNB negative patients with cutaneous melanoma does not influence OS
Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin
Please login below to download this issue (PDF)